-

GE HealthCare Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (“GE HealthCare”) announced today that it received notice on January 5, 2026, of an unsolicited “mini-tender” offer by Potemkin Limited to purchase up to 100,000 shares (or a greater amount as outlined in the offer documentation) of GE HealthCare common stock at a price of $54.20 per share in cash. Potemkin Limited’s offer price of $54.20 per share is approximately 34.77 percent lower than the $83.09 closing per share price of GE HealthCare’s common stock on December 8, 2025, the last trading day before the mini-tender offer appears to have commenced.

GE HealthCare does not endorse Potemkin Limited’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to Potemkin Limited’s offer because the offer is at a price that is significantly below the current market price for GE HealthCare’s common stock and subject to numerous conditions.

GE HealthCare is not affiliated or associated in any way with Potemkin Limited, its mini-tender offer or its offer documentation. Potemkin Limited has made similar mini-tender offers for shares of other companies. Mini-tender offers seek to acquire less than five percent of a company’s outstanding shares, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (the “SEC”) that apply to offers of more than five percent of company’s outstanding shares. As a result, mini-tender offers do not provide investors with the same level of protections as provided for larger tender offers under U.S. securities laws.

The SEC has cautioned investors that some bidders making mini-tender offers at below-market prices are “hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” More on the SEC’s guidance to investors on mini-tender offers is available at https://www.sec.gov/about/reports-publications/investorpubsminitend.

GE HealthCare urges investors to obtain current market quotations for their shares, to consult with their broker or financial advisor and to exercise caution with respect to Potemkin Limited’s offer. GE HealthCare recommends that stockholders who have not responded to Potemkin Limited’s offer take no action. Stockholders who have already tendered their shares may withdraw them no more than 14 days after the date of delivery of the stockholder’s acceptance form to the depositary for this offer, in accordance with Potemkin Limited’s offer documentation. The offer is currently scheduled to expire at 5:00 p.m., New York City time, on June 9, 2026. Potemkin Limited may extend the offering period at its discretion.

GE HealthCare encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure at https://www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

GE HealthCare requests that a copy of this release be included with all distributions relating to Potemkin Limited’s mini-tender offer for shares of GE HealthCare common stock.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
caroylnne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
M +1 414 530 3027
jennifer.r.fox@gehealthcare.com

GE HealthCare Technologies Inc.

NASDAQ:GEHC

Release Versions

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
caroylnne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
M +1 414 530 3027
jennifer.r.fox@gehealthcare.com

More News From GE HealthCare Technologies Inc.

GE HealthCare announces U.S. FDA 510(k) clearance for View, a next‑generation diagnostic viewer enabling anywhere‑access to radiologists

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that View, the powerful viewer within the Genesis™ Radiology Workspace, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Designed as a fast, diagnostic, zero‑footprint viewer, View serves as the core anchor of the Genesis Radiology Workspace.2 This next‑generation solution aims to transform radiology workflows, unify the user experience, and empower radiologists with greater efficiency and precision. Studies...

GE HealthCare to showcase AI and digital leadership at HIMSS 2026

LAS VEGAS--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will showcase innovations moving healthcare forward at the Health Information and Management Systems Society (HIMSS) Global Health Conference & Exhibition 2026 in Las Vegas from March 9-12, 2026. This year, GE HealthCare will spotlight meaningful technology transforming the way healthcare professionals approach patient care, from imaging operations and fleet management to enterprise solutions, ultrasound, and patient care technologies...

GE HealthCare achieves MRI portfolio milestone with FDA clearances for next-generation SIGNA MRI technology designed to enhance precision imaging and clinical efficiency

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today 510(k) clearance of three new magnetic resonance (MR) innovations with the U.S. Food and Drug Administration (FDA): SIGNA™ Sprint with Freelium™1, a 1.5T sealed magnet MRI system; SIGNA™ Bolt2, an advanced 3T MRI scanner; and SIGNA™ One3, an AI-driven ecosystem of workflow solutions designed to help reduce inefficiencies and support MRI exams from plan to scan and beyond. The new MRI systems and technology combat some of the...
Back to Newsroom